NO320074B1 - Fremgangsmater for fremstilling av proteosom-amfifil-determinant vaksine, samt multivalent vaksine fremstilt i folge fremgangsmaten. - Google Patents

Fremgangsmater for fremstilling av proteosom-amfifil-determinant vaksine, samt multivalent vaksine fremstilt i folge fremgangsmaten. Download PDF

Info

Publication number: NO320074B1
Authority: NO; Norway
Prior art keywords: proteosome; determinant; amphiphile; vaccine according; vaccine
Prior art date: 1995-09-18

Application number

NO19981189A

Other languages

English (en)

Norwegian (no)

Other versions

NO981189L (no

NO981189D0 (no

Inventor

George H Lowell

Wendell D Zollinger

James F Woods

Original Assignee

Id Biomedical Corp Of Maryland

Us Army Medical Res Material C

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-09-18

Filing date

1998-03-17

Publication date

2005-10-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21707938&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO320074(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-03-17 Application filed by Id Biomedical Corp Of Maryland, Us Army Medical Res Material C filed Critical Id Biomedical Corp Of Maryland

1998-03-17 Publication of NO981189D0 publication Critical patent/NO981189D0/no

1998-05-14 Publication of NO981189L publication Critical patent/NO981189L/no

2005-10-17 Publication of NO320074B1 publication Critical patent/NO320074B1/no

Links

229960005486 vaccine Drugs 0.000 title claims abstract description 128
238000000034 method Methods 0.000 title claims abstract description 58
229940031348 multivalent vaccine Drugs 0.000 title claims abstract description 11
229920006008 lipopolysaccharide Polymers 0.000 claims abstract description 112
239000002158 endotoxin Substances 0.000 claims abstract description 111
238000004519 manufacturing process Methods 0.000 claims abstract description 40
238000000108 ultra-filtration Methods 0.000 claims abstract description 23
241000607760 Shigella sonnei Species 0.000 claims abstract description 20
238000011026 diafiltration Methods 0.000 claims abstract description 17
241000606999 Plesiomonas shigelloides Species 0.000 claims abstract description 16
230000008569 process Effects 0.000 claims abstract description 11
238000012544 monitoring process Methods 0.000 claims abstract description 7
241000894006 Bacteria Species 0.000 claims abstract description 6
239000003599 detergent Substances 0.000 claims abstract description 3
241000607762 Shigella flexneri Species 0.000 claims abstract 2
239000004094 surface-active agent Substances 0.000 claims description 32
DVEKCXOJTLDBFE-UHFFFAOYSA-N n-dodecyl-n,n-dimethylglycinate Chemical group CCCCCCCCCCCC[N+](C)(C)CC([O-])=O DVEKCXOJTLDBFE-UHFFFAOYSA-N 0.000 claims description 19
239000012466 permeate Substances 0.000 claims description 19
239000012510 hollow fiber Substances 0.000 claims description 16
239000012528 membrane Substances 0.000 claims description 14
239000012465 retentate Substances 0.000 claims description 14
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 12
241000607768 Shigella Species 0.000 claims description 10
239000000203 mixture Substances 0.000 claims description 10
241000588653 Neisseria Species 0.000 claims description 8
238000005259 measurement Methods 0.000 claims description 8
239000011148 porous material Substances 0.000 claims description 8
229940115939 shigella sonnei Drugs 0.000 claims description 8
230000004888 barrier function Effects 0.000 claims description 5
239000002244 precipitate Substances 0.000 claims description 5
238000002156 mixing Methods 0.000 claims description 4
230000015572 biosynthetic process Effects 0.000 claims description 3
241000607766 Shigella boydii Species 0.000 claims description 2
230000009918 complex formation Effects 0.000 claims description 2
241000607000 Plesiomonas Species 0.000 claims 2
238000011084 recovery Methods 0.000 claims 2
230000003247 decreasing effect Effects 0.000 claims 1
230000003287 optical effect Effects 0.000 claims 1
239000013049 sediment Substances 0.000 claims 1
238000002360 preparation method Methods 0.000 abstract description 30
238000000502 dialysis Methods 0.000 abstract description 18
238000005516 engineering process Methods 0.000 abstract description 16
238000011109 contamination Methods 0.000 abstract description 8
230000007423 decrease Effects 0.000 abstract description 3
230000000890 antigenic effect Effects 0.000 abstract 1
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
230000003053 immunization Effects 0.000 description 22
238000002649 immunization Methods 0.000 description 22
241000699670 Mus sp. Species 0.000 description 19
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
238000010668 complexation reaction Methods 0.000 description 18
239000000243 solution Substances 0.000 description 18
102000004169 proteins and genes Human genes 0.000 description 16
108090000623 proteins and genes Proteins 0.000 description 16
241000147000 Shigella flexneri 2a Species 0.000 description 15
230000005847 immunogenicity Effects 0.000 description 12
230000004044 response Effects 0.000 description 12
206010040550 Shigella infections Diseases 0.000 description 11
239000000872 buffer Substances 0.000 description 11
210000004379 membrane Anatomy 0.000 description 11
239000000047 product Substances 0.000 description 11
238000012360 testing method Methods 0.000 description 11
208000004429 Bacillary Dysentery Diseases 0.000 description 10
201000005113 shigellosis Diseases 0.000 description 10
201000010099 disease Diseases 0.000 description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
238000001556 precipitation Methods 0.000 description 9
238000003756 stirring Methods 0.000 description 9
101710116435 Outer membrane protein Proteins 0.000 description 8
108090000765 processed proteins & peptides Proteins 0.000 description 8
210000002966 serum Anatomy 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
239000007983 Tris buffer Substances 0.000 description 7
230000005875 antibody response Effects 0.000 description 7
238000011194 good manufacturing practice Methods 0.000 description 7
239000007788 liquid Substances 0.000 description 7
239000000463 material Substances 0.000 description 7
102000004196 processed proteins & peptides Human genes 0.000 description 7
239000000427 antigen Substances 0.000 description 6
230000002163 immunogen Effects 0.000 description 6
206010035664 Pneumonia Diseases 0.000 description 5
238000004140 cleaning Methods 0.000 description 5
238000001914 filtration Methods 0.000 description 5
239000012530 fluid Substances 0.000 description 5
238000004128 high performance liquid chromatography Methods 0.000 description 5
230000002209 hydrophobic effect Effects 0.000 description 5
230000028993 immune response Effects 0.000 description 5
231100000518 lethal Toxicity 0.000 description 5
230000001665 lethal effect Effects 0.000 description 5
238000013341 scale-up Methods 0.000 description 5
238000013207 serial dilution Methods 0.000 description 5
238000011146 sterile filtration Methods 0.000 description 5
238000012546 transfer Methods 0.000 description 5
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
108010028921 Lipopeptides Proteins 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
238000010171 animal model Methods 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
150000004676 glycans Chemical class 0.000 description 4
230000000968 intestinal effect Effects 0.000 description 4
229920001282 polysaccharide Polymers 0.000 description 4
239000005017 polysaccharide Substances 0.000 description 4
238000005406 washing Methods 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
238000011161 development Methods 0.000 description 3
238000000635 electron micrograph Methods 0.000 description 3
238000010828 elution Methods 0.000 description 3
238000011049 filling Methods 0.000 description 3
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
239000010931 gold Substances 0.000 description 3
229910052737 gold Inorganic materials 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
230000036039 immunity Effects 0.000 description 3
230000002434 immunopotentiative effect Effects 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
230000000241 respiratory effect Effects 0.000 description 3
210000003296 saliva Anatomy 0.000 description 3
238000005070 sampling Methods 0.000 description 3
210000002700 urine Anatomy 0.000 description 3
238000012795 verification Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 2
108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 2
239000012506 Sephacryl® Substances 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000000844 anti-bacterial effect Effects 0.000 description 2
210000000628 antibody-producing cell Anatomy 0.000 description 2
238000003556 assay Methods 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
150000002270 gangliosides Chemical class 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
210000002011 intestinal secretion Anatomy 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
229940023041 peptide vaccine Drugs 0.000 description 2
210000005259 peripheral blood Anatomy 0.000 description 2
239000011886 peripheral blood Substances 0.000 description 2
229920001296 polysiloxane Polymers 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000004064 recycling Methods 0.000 description 2
210000002345 respiratory system Anatomy 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
230000000392 somatic effect Effects 0.000 description 2
238000003860 storage Methods 0.000 description 2
229940031626 subunit vaccine Drugs 0.000 description 2
238000010257 thawing Methods 0.000 description 2
230000002485 urinary effect Effects 0.000 description 2
101710099705 Anti-lipopolysaccharide factor Proteins 0.000 description 1
239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000588722 Escherichia Species 0.000 description 1
101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
238000000729 Fisher's exact test Methods 0.000 description 1
229930186217 Glycolipid Natural products 0.000 description 1
241000606790 Haemophilus Species 0.000 description 1
241000588748 Klebsiella Species 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229920002274 Nalgene Polymers 0.000 description 1
241000588652 Neisseria gonorrhoeae Species 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
229940024546 aluminum hydroxide gel Drugs 0.000 description 1
SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
210000000776 antibody secreting cell Anatomy 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000011324 bead Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000012459 cleaning agent Substances 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000005056 compaction Methods 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
239000000385 dialysis solution Substances 0.000 description 1
238000007865 diluting Methods 0.000 description 1
235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
238000012500 good manufacturing practice method Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000036512 infertility Effects 0.000 description 1
230000035987 intoxication Effects 0.000 description 1
231100000566 intoxication Toxicity 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
-1 liposaccharides Polymers 0.000 description 1
239000002502 liposome Substances 0.000 description 1
230000008949 local secretion Effects 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
239000007908 nanoemulsion Substances 0.000 description 1
238000012856 packing Methods 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000002572 peristaltic effect Effects 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
230000002516 postimmunization Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000037452 priming Effects 0.000 description 1
229940023143 protein vaccine Drugs 0.000 description 1
238000005086 pumping Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000011012 sanitization Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
239000011232 storage material Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229940031572 toxoid vaccine Drugs 0.000 description 1
230000032258 transport Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
238000013060 ultrafiltration and diafiltration Methods 0.000 description 1
208000019206 urinary tract infection Diseases 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
239000012646 vaccine adjuvant Substances 0.000 description 1
229940124931 vaccine adjuvant Drugs 0.000 description 1
239000003981 vehicle Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/008—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from microorganisms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/25—Shigella (G)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Food Science & Technology (AREA)
Polymers & Plastics (AREA)
Oncology (AREA)
Dispersion Chemistry (AREA)
Mycology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

NO19981189A 1995-09-18 1998-03-17 Fremgangsmater for fremstilling av proteosom-amfifil-determinant vaksine, samt multivalent vaksine fremstilt i folge fremgangsmaten. NO320074B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US385995P	1995-09-18	1995-09-18
PCT/US1996/015002 WO1997010844A1 (en)	1995-09-18	1996-09-18	Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines

Publications (3)

Publication Number	Publication Date
NO981189D0 NO981189D0 (no)	1998-03-17
NO981189L NO981189L (no)	1998-05-14
NO320074B1 true NO320074B1 (no)	2005-10-17

Family

ID=21707938

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19981189A NO320074B1 (no)	1995-09-18	1998-03-17	Fremgangsmater for fremstilling av proteosom-amfifil-determinant vaksine, samt multivalent vaksine fremstilt i folge fremgangsmaten.

Country Status (20)

Country	Link
US (1)	US6476201B1 (zh)
EP (1)	EP0854729B2 (zh)
JP (2)	JP4033489B2 (zh)
KR (1)	KR19990045763A (zh)
CN (1)	CN1211192A (zh)
AT (1)	ATE261313T1 (zh)
BR (1)	BR9610484A (zh)
CA (1)	CA2232410C (zh)
CZ (1)	CZ298460B6 (zh)
DE (1)	DE69631835T3 (zh)
DK (1)	DK0854729T3 (zh)
EA (1)	EA199800208A1 (zh)
ES (1)	ES2217325T5 (zh)
HU (1)	HUP9901577A3 (zh)
IL (1)	IL123720A (zh)
MX (1)	MX9802128A (zh)
NO (1)	NO320074B1 (zh)
PL (1)	PL325604A1 (zh)
PT (1)	PT854729E (zh)
WO (1)	WO1997010844A1 (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5961970A (en)	1993-10-29	1999-10-05	Pharmos Corporation	Submicron emulsions as vaccine adjuvants
ES2278446T3 (es) *	1998-05-29	2007-08-01	Novartis Vaccines And Diagnostics, Inc.	Vacunas combinadas b/c contra la meningitis.
EP1228217B1 (en)	1999-04-30	2012-11-21	Novartis Vaccines and Diagnostics S.r.l.	Conserved neisserial antigens
MXPA01011867A (es)	1999-05-19	2002-05-06	Chiron Spa	Composiciones neisseriales de combinacion.
DE60121136T2 (de) *	2000-02-15	2007-06-06	Id Biomedical Corporation Of Quebec, Ville St. Laurent	Proteasom-influenzavirus-impfstoffzusammensetzung
EP1721618A3 (en) *	2000-02-15	2007-01-10	ID Biomedical Corporation of Quebec	Proteosome influenza vaccine composition
JP4763210B2 (ja)	2000-02-28	2011-08-31	ノバルティスヴァクシンズアンドダイアグノスティクスエスアールエル	ナイセリアのタンパク質の異種発現
WO2002072012A2 (en)	2001-03-09	2002-09-19	Id Biomedical Corporation Of Quebec	A novel proteosome-liposaccharide vaccine adjuvant
EP2255826B1 (en) *	2002-08-02	2016-04-13	GlaxoSmithKline Biologicals S.A.	Neisserial vaccine compositions comprising a combination of antigens
PT2353608T (pt) *	2002-10-11	2020-03-11	Novartis Vaccines And Diagnostics S R L	Vacinas de polipéptidos para protecção alargada contra linhagens meningocócicas hipervirulentas
US7255867B2 (en) *	2002-11-15	2007-08-14	Id Biomedical Corporation Of Quebec	Vaccine
GB0316560D0 (en) *	2003-07-15	2003-08-20	Chiron Srl	Vesicle filtration
US7368537B2 (en) *	2003-07-15	2008-05-06	Id Biomedical Corporation Of Quebec	Subunit vaccine against respiratory syncytial virus infection
WO2005027964A1 (en) *	2003-09-15	2005-03-31	Id Biomedical Corporation Of Quebec	Measles subunit vaccine
JP4966661B2 (ja) *	2003-10-22	2012-07-04	アイディーバイオメディカルコーポレイションオブケベック	生得的免疫およびアレルギー性免疫を活性化させるための組成物および方法
SG186686A1 (en)	2004-06-25	2013-01-30	Id Biomedical Corp Quebec	Compositions and methods for treating neurological disorders
EP1778283A2 (en) *	2004-06-30	2007-05-02	ID Biomedical Corporation of Quebec	Vaccine compositions for treating coronavirus infection
US7552948B2 (en)	2006-03-29	2009-06-30	Tokai Rubber Industries, Ltd.	Quick connector
ZA200900899B (en) *	2006-08-07	2010-07-28	Harvard College	Protein matrix vaccines and methods of making and administering such vaccines
TWI565713B (zh)	2006-08-07	2017-01-11	哈佛大學校長及研究員協會	蛋白基質疫苗以及該疫苗的製造與使用方法
US20100288029A1 (en) *	2006-08-30	2010-11-18	Ge Healthcar Bio-Sciences Corp.	System and method for characterizing membranes and membrane filtration devices
JP5723768B2 (ja) *	2008-05-30	2015-05-27	ザユナイテッドステイツオブアメリカ，アズレプレゼンテッドバイザセクレタリーオブジアーミー，オンビハーフオブウォルターリードアーミーインスティチュートオブリサーチ	髄膜炎菌性多価未変性外膜小胞ワクチン、その作製方法およびその使用
AU2010292195A1 (en) *	2009-09-09	2012-03-15	Matrivax Research & Development Corp.	Protein matrix vaccines of improved immunogenicity
AU2015321698B2 (en) *	2014-09-24	2018-06-28	The United States Of America As Represented By The Secretary Of The Navy	Combined enterotoxigenic Escherichia coli and Campylobacter jejuni recombinant construct
CA3208643A1 (en)	2021-01-18	2022-07-21	Conserv Bioscience Limited	Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4707543A (en) *	1985-09-17	1987-11-17	The United States Of America As Represented By The Secretary Of The Army	Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
RU1522494C (ru) *	1987-06-16	1994-11-15	Научно-производственное объединение "Иммунопрепарат"	Способ получения инактивированной вакцины гриппа
JPH01125328A (ja) *	1987-07-30	1989-05-17	Centro Natl De Biopreparados	髄膜炎菌ワクチン
US5145702A (en) *	1988-09-19	1992-09-08	Opta Food Ingredients, Inc.	Hydrophobic protein microparticles and preparation thereof
ATE120093T1 (de) *	1988-12-19	1995-04-15	Praxis Biolog Inc	Meningococcales klasse i-aussenmembranprotein- vakzin.
US5102989A (en) *	1991-03-15	1992-04-07	Merck & Co., Inc.	Method of stabilizing recombinant hepatitis B virus surface proteins from recombinant host cells
WO1994002626A1 (en) *	1992-07-20	1994-02-03	Merck & Co., Inc.	Immunological conjugates of ompc and hiv-specific selected principal neutralization epitopes
US5576016A (en) *	1993-05-18	1996-11-19	Pharmos Corporation	Solid fat nanoemulsions as drug delivery vehicles
AU5543294A (en) *	1993-10-29	1995-05-22	Pharmos Corp.	Submicron emulsions as vaccine adjuvants
DE60121136T2 (de) *	2000-02-15	2007-06-06	Id Biomedical Corporation Of Quebec, Ville St. Laurent	Proteasom-influenzavirus-impfstoffzusammensetzung

1996
- 1996-09-18 ES ES96932269T patent/ES2217325T5/es not_active Expired - Lifetime
- 1996-09-18 WO PCT/US1996/015002 patent/WO1997010844A1/en active IP Right Grant
- 1996-09-18 PT PT96932269T patent/PT854729E/pt unknown
- 1996-09-18 CA CA002232410A patent/CA2232410C/en not_active Expired - Lifetime
- 1996-09-18 DE DE69631835T patent/DE69631835T3/de not_active Expired - Lifetime
- 1996-09-18 PL PL96325604A patent/PL325604A1/xx unknown
- 1996-09-18 BR BR9610484-8A patent/BR9610484A/pt not_active Application Discontinuation
- 1996-09-18 US US09/043,529 patent/US6476201B1/en not_active Expired - Lifetime
- 1996-09-18 KR KR1019980702007A patent/KR19990045763A/ko not_active Application Discontinuation
- 1996-09-18 CZ CZ0081998A patent/CZ298460B6/cs not_active IP Right Cessation
- 1996-09-18 IL IL12372096A patent/IL123720A/en not_active IP Right Cessation
- 1996-09-18 EP EP96932269A patent/EP0854729B2/en not_active Expired - Lifetime
- 1996-09-18 HU HU9901577A patent/HUP9901577A3/hu unknown
- 1996-09-18 CN CN96197616A patent/CN1211192A/zh active Pending
- 1996-09-18 DK DK96932269T patent/DK0854729T3/da active
- 1996-09-18 JP JP51287597A patent/JP4033489B2/ja not_active Expired - Lifetime
- 1996-09-18 EA EA199800208A patent/EA199800208A1/ru unknown
- 1996-09-18 AT AT96932269T patent/ATE261313T1/de not_active IP Right Cessation
1998
- 1998-03-17 NO NO19981189A patent/NO320074B1/no not_active IP Right Cessation
- 1998-03-18 MX MX9802128A patent/MX9802128A/es unknown
2003
- 2003-10-24 JP JP2003365270A patent/JP2004099619A/ja active Pending

Also Published As

Publication number	Publication date
CA2232410C (en)	2003-06-17
PL325604A1 (en)	1998-08-03
MX9802128A (es)	1998-11-29
BR9610484A (pt)	2001-09-11
US6476201B1 (en)	2002-11-05
EP0854729B1 (en)	2004-03-10
NO981189L (no)	1998-05-14
DE69631835T3 (de)	2009-03-05
IL123720A (en)	2002-02-10
CZ81998A3 (cs)	1998-10-14
CN1211192A (zh)	1999-03-17
EA199800208A1 (ru)	1998-10-29
NO981189D0 (no)	1998-03-17
PT854729E (pt)	2004-08-31
HUP9901577A2 (hu)	1999-08-30
JP2004099619A (ja)	2004-04-02
EP0854729A1 (en)	1998-07-29
EP0854729B2 (en)	2008-10-22
CA2232410A1 (en)	1997-03-27
JP2000507913A (ja)	2000-06-27
ES2217325T5 (es)	2009-04-01
DE69631835T2 (de)	2005-02-10
DK0854729T3 (da)	2004-07-12
KR19990045763A (ko)	1999-06-25
JP4033489B2 (ja)	2008-01-16
WO1997010844A1 (en)	1997-03-27
CZ298460B6 (cs)	2007-10-10
ES2217325T3 (es)	2004-11-01
EP0854729A4 (en)	2000-02-02
HUP9901577A3 (en)	2000-03-28
ATE261313T1 (de)	2004-03-15
DE69631835D1 (de)	2004-04-15
US20020164357A1 (en)	2002-11-07
IL123720A0 (en)	1998-10-30

Legal Events

Date	Code	Title	Description
2016-09-26	MK1K	Patent expired

Publication	Publication Date	Title
NO320074B1 (no)	2005-10-17	Fremgangsmater for fremstilling av proteosom-amfifil-determinant vaksine, samt multivalent vaksine fremstilt i folge fremgangsmaten.
CA2123355C (en)	2007-08-28	Preparation and uses of los-depleted outer membrane proteins of gram-negative cocci
US6558677B2 (en)	2003-05-06	Vaccine against gram negative bacteria
Collins	2011	Gram-negative outer membrane vesicles in vaccine development
US11339367B2 (en)	2022-05-24	Hyperblebbing Shigella strains
Levine et al.	2020	Fimbrial vaccines
Frasch et al.	1982	Protection against group B Neisseria meningitidis disease: preparation of soluble protein and protein-polysaccharide immunogens
Frasch et al.	2001	Outer membrane protein vesicle vaccines for meningococcal disease
US20040131642A1 (en)	2004-07-08	Outer membrane vesicle vaccine against disease caused by neisseria meningitidis serogroup a and process for the production thereof
BE1022875B1 (fr)	2016-09-30	Compositions pour une immunisation contre staphylococcus aureus
US20130017219A1 (en)	2013-01-17	Purification of bacterial vesicles
AU2010269961A1 (en)	2012-02-02	Conserved Escherichia coli immunogens
AU751063B2 (en)	2002-08-08	Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines
Ito et al.	2009	Homologous prime-boost strategy in neonate mice using Neisseria lactamica